Drug intelligence / Profile preview

INCB-054329

Development stage: Preclinical
Lead developer: Incyte
Modality: Small Molecules
Administration: Oral

Overview

INCB-054329 is a **bromodomain and extra-terminal (BET) inhibitor**, specifically targeting BRD2, BRD3, and BRD4. It has been investigated for its potential in treating **advanced malignancies**, including various solid tumors and lymphomas. Developed by **Incyte Corporation**, it was studied in a Phase 1/2 clinical trial to evaluate its safety, tolerability, and efficacy in patients with advanced cancers.

Targets

BRD3 (Bromodomain-containing protein 3)BRD4 (Bromodomain-containing protein 4)BRD2 (Bromodomain-containing protein 2)

Beyond the preview

Go deeper on INCB-054329.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INCB-054329.

Explore the full profile